Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
60,928.61 +118.86 (+0.20%) CMC Crypto 200
1,261.20 -96.81 (-7.13%)
Daiichi Sankyo Company, Limited (D4S.F)
| Previous close | 30.67 |
| Open | 31.52 |
| Bid | 31.60 x 50000 |
| Ask | 32.54 x 50000 |
| Day's range | 31.52 - 32.56 |
| 52-week range | 22.35 - 34.48 |
| Volume | |
| Avg. volume | 200 |
| Market cap | 62.434B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 51.68 |
| EPS (TTM) | 0.63 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | 0.36 (1.11%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
BenzingaHeart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million. The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05. U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growt
Business WireENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
Yahoo FinanceAstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
